fashion -WSS

fashion

author：entertainment 2025-08-11 11:44:00 - browse：52717

Mel Evans/AP

Merck announced Monday it will acquire Harpoon Therapeutics and its pipeline of immune-based cancer drugs for $680 million. Merck will pay $23 per share, just over twice Harpoon’s market price entering the week.

The bolt-on deal comes as Merck’s top brass searches for ways to bolster the company’s revenue after it loses exclusivity on Keytruda, long the world’s most lucrative cancer drug. That could come as soon as 2028.

Keytruda, a PD-(L)1 inhibitor, works by turning off a “brake” on T cells, allowing roving immune cells to attack tumors. Harpoon’s pipeline belongs to a new class of cancer drugs designed to grab onto the T cells and tumor cells and bring them together.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： BioAge raises $170M for combination therapy with Zepbound

knowledge

WSS

For Medicare Advantage, Democrats want stronger protections around AI

The dental labor crisis is a moment of opportunity

Biden report: The neurospychology of memory and aging

'Revelatory' study finds a smoking impact that remains after quitting

Why did Pfizer dish out millions for a Super Bowl ad?

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

entertainment

fashion

focus

Activists slam private health insurers over coverage restrictions

What STAT readers think about the FDA and patient advocacy

23andMe had bad news about my health. I wish a person had delivered it

Industry veterans launch new biotech VC with $310M

Apple is now the first public company to be valued at $3 trillion

Medical mystery: When a cough is not just a cough

Affirmative action in medical school literally saved lives

A disappointing year of Humira biosimilars

How to save PrEP access — and even expand it

Why health care costs have stayed mostly flat since 2010

hotspot

CRISPR gene editing developments we’re watching in 2024

Can sheer will power keep patients alive in their dying hours?

Keeping primary care docs in field isn't impossible, says AAFP CEO

How to keep neuroscience’s past racism from being its future

Biogen Alzheimer’s drug launch off to slow start

Biogen Alzheimer’s drug launch off to slow start

knowledge

knowledge

knowledge

leisure time